Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab and Tuvonralimab”

100 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 100 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT07389629
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Who this might be right for
Iparomlimab and TuvonralimabClear Cell Renal Cell CarcinomaNeoadjuvant Therapy
Sun Yat-sen University 25
Testing effectiveness (Phase 2)Looking for participantsNCT07099274
What this trial is testing

Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma

Who this might be right for
HCC
Tianjin Medical University Cancer Institute and Hospital 29
Testing effectiveness (Phase 2)Looking for participantsNCT06908382
What this trial is testing

Neoadjuvant QL1706 Therapy for ESCC

Who this might be right for
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Shandong Provincial Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07200947
What this trial is testing

A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Who this might be right for
SMARCA4-Deficient TumorLocally Advanced or Metastatic Non-Small Cell Lung Cancer
Zhijie Wang 28
Testing effectiveness (Phase 2)Looking for participantsNCT07082179
What this trial is testing

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Jiangsu Cancer Institute & Hospital 33
Testing effectiveness (Phase 2)Looking for participantsNCT06878222
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Who this might be right for
Cervical Cancers
Obstetrics & Gynecology Hospital of Fudan University 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07119931
What this trial is testing

A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)

Who this might be right for
HCC
Tianjin Medical University Cancer Institute and Hospital 34
Testing effectiveness (Phase 2)Looking for participantsNCT06911684
What this trial is testing

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

Who this might be right for
Rectal Cancer Patients
Sun Yat-sen University 88
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07407452
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancers
Jiangsu Cancer Institute & Hospital 50
Not applicableNot Yet RecruitingNCT07139587
What this trial is testing

The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Qingxia Li 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07502014
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer (CRC)mCRC
Huazhong University of Science and Technology 60
Not applicableNot Yet RecruitingNCT07538193
What this trial is testing

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung (NSCLC)Neoplasm StagingLymphatic Metastasis
Tang-Du Hospital 28
Testing effectiveness (Phase 2)Looking for participantsNCT06942416
What this trial is testing

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Who this might be right for
Cervical CancerNeoplasm Recurrence, LocalOligometastatic
Shandong Cancer Hospital and Institute 36
Testing effectiveness (Phase 2)Looking for participantsNCT06941766
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Who this might be right for
Intermediate Trophoblastic Tumor
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT07290010
What this trial is testing

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital 25
Testing effectiveness (Phase 2)Looking for participantsNCT07530445
What this trial is testing

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Who this might be right for
Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Looking for participantsNCT07165847
What this trial is testing

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Who this might be right for
ImmunotherapyGastric Cancer (GC)Radiotherapy+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07156682
What this trial is testing

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

Who this might be right for
Colon CancerMSS/pMMRQL1706
Qilu Hospital of Shandong University 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07446387
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer (CRC)
Jiangsu Cancer Institute & Hospital 70
Load More Results